BioArctic's Leqembi Receives Approval for IV Maintenance Use
BioArctic AB's (publ) partner has announced that lecanemab, branded as Leqembi, has received approval for intravenous (IV) maintenance therapy for early Alzheimer's disease in China. This significant milestone allows for dosing every four weeks, making it a more convenient option for patients and caregivers alike.
Transitioning to IV Maintenance Dosing
Initially approved for Alzheimer's disease treatment in January 2024, the drug targets individuals experiencing mild cognitive impairment or mild dementia. After a comprehensive 18-month treatment protocol, patients may transition to the maintenance regimen of 10 mg/kg once every four weeks, or they may continue on the more frequent dosing schedule if clinically appropriate.
Understanding Alzheimer's Disease
Alzheimer's disease (AD) is a complex, progressive condition characterized by the buildup of amyloid-beta plaques and tau protein tangles in the brain. These harmful deposits contribute to cognitive decline and memory loss. Lecanemab uniquely addresses AD by attacking both types of proteins, making it a groundbreaking option in this therapeutic area.
BioArctic and Eisai Collaboration
The development of Leqembi has been the result of a long-term partnership between BioArctic and Eisai. The antibody formulation evolved from research led by Professor Lars Lannfelt. Eisai is charged with the ongoing clinical development, including market application processes and commercialization responsibilities. BioArctic retains rights for commercialization in the Nordic region.
Details of Clinical Studies and Ongoing Trials
Recent clinical studies have demonstrated the drug's efficacy and safety. In particular, the ongoing Phase 3 study (AHEAD 3-45) investigates the potential of lecanemab in preclinical Alzheimer's disease, an area of keen interest. This study, which involves a robust public-private partnership, was fully recruited by October 2024 and has attracted significant attention in the research community.
Global Reach and Future Potential
Lecanemab is now approved in 50 countries, including major markets like the U.S., Japan, and numerous European nations. Its approval marks a pivotal moment for BioArctic as the company expands its reach with Leqembi while pursuing additional regulatory reviews across various countries. A secondary formulation, Leqembi Iqlik™, is being developed for subcutaneous delivery, providing additional flexibility in patient treatment choices.
BioArctic’s Research Focus and Future Projects
BioArctic remains dedicated to research in neurodegenerative diseases beyond Alzheimer's. The company boasts a diverse portfolio targeting conditions such as Parkinson’s disease and ALS. Innovations like the BrainTransporter™ technology further exemplify their commitment to enhancing therapeutic delivery across the blood-brain barrier, which could significantly improve treatment outcomes.
About BioArctic AB
BioArctic AB is a pioneering research-driven biopharmaceutical company specializing in innovative therapies aimed at treating neurodegenerative diseases. The company is renowned for developing Leqembi, the world’s first FDA-approved drug shown to effectively slow down Alzheimer’s progression. BioArctic continues to advance its mission, pursuing next-generation therapies and expanding its capabilities in transformative health solutions.
Frequently Asked Questions
What is Leqembi?
Leqembi, or lecanemab, is a monoclonal antibody designed to treat Alzheimer’s disease by targeting amyloid-beta plaques and tau proteins in the brain.
How was Leqembi approved for use?
Leqembi gained approval through rigorous clinical trials demonstrating its efficacy and safety in treating early Alzheimer's disease.
What are the dosage options for Leqembi?
Patients may initially receive 10 mg/kg every two weeks, transitioning to once every four weeks for maintenance therapy as determined by their healthcare provider.
What does BioArctic focus on?
BioArctic focuses on research and development of innovative treatments for neurodegenerative diseases, with an emphasis on Alzheimer's, Parkinson’s, and ALS.
How can patients access Leqembi?
Patients should consult their healthcare providers to learn more about accessing Leqembi and discussing appropriate treatment plans based on their individual health needs.
